Bausch + Lomb (BLCO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors o ...

Intellectual Property and Regulatory Exclusivity - The company owns or exclusively licenses approximately 2,499 granted patents worldwide, with about 476 being U.S. patents[50]. - Approximately 83% of the issued patents are set to expire within the next 10 years, with 22 patents expiring in 2026, 37 in 2027, and 26 in 2028[50]. - The company relies on a combination of regulatory and patent rights to protect the value of its product investments[49]. - The U.S. Hatch-Waxman Act provides five years of non-patent regulatory exclusivity from the first FDA approval of a new drug compound[52]. - In the EU, a similar data exclusivity scheme allows the pioneer drug company to use data obtained at its expense for up to eight years from the first approval[53]. - The Biologics Price Competition and Innovation Act grants 12 years of market exclusivity for reference biological products[55]. - The Orphan Drug Act allows for seven years of marketing exclusivity for the first approved orphan drug for a rare disease[56]. - Canada provides an eight-year data exclusivity period for innovative drugs from the date of market approval[58]. Compliance and Regulatory Challenges - Compliance with extensive government regulations is required for the research, development, and marketing of pharmaceutical products and medical devices[61]. - The company is subject to extensive U.S. federal and state health care marketing regulations, including the federal False Claims Act, which imposes civil and criminal liability for false claims[68]. - The Physician Payment Sunshine Act requires pharmaceutical companies to report any "transfer of value" to prescribers, with significant penalties for non-compliance[69]. - The company must comply with the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws, which could result in criminal or civil penalties for violations[70]. - Compliance with the Health Insurance Portability and Accountability Act (HIPAA) is mandatory, requiring safeguards for the protection of sensitive health information[71]. - The California Consumer Privacy Act (CCPA) imposes stringent data privacy requirements, including civil penalties for violations and a private right of action for data breaches[73]. - The General Data Protection Regulation (GDPR) allows for fines of up to 4% of global annual revenue or €20 million for certain violations, significantly impacting data processing practices[75]. - The company faces compliance challenges due to differing interpretations of data protection laws in the EU and the UK, which may lead to increased operational costs[76]. - The Personal Information Protection Law (PIPL) in China imposes specific requirements for transferring personal data outside the country, affecting international operations[81]. - The company must navigate various state and federal laws regulating artificial intelligence (AI), which could require substantial changes to AI practices and incur compliance costs[78]. Market and Financial Considerations - Successful commercialization of products may depend on government and third-party payor reimbursement, with increasing pressures to limit or regulate prices in key markets[83]. - The Inflation Reduction Act (IRA) imposes financial penalties on drug price increases exceeding inflation rates, with Medicare Part D redesign starting in 2025, capping out-of-pocket costs at $2,000 for beneficiaries[87]. - Approximately 37% of the company's product sales for 2025 are produced, in total or in part, by third-party manufacturers under manufacturing arrangements[107]. - The company has a global commercial team of approximately 4,200 employees, with around 1,050 dedicated to the U.S. market for contact lenses, lens care, and pharmaceuticals[96][97]. - Customers accounting for 10% or more of total revenues include McKesson Corporation and Cardinal Health, each contributing 10% in 2025[100]. - The company operates 25 manufacturing facilities across 11 countries, focusing on specific product categories to meet regulatory requirements[103]. - As of December 31, 2025, the company employed approximately 13,000 individuals, with 7,000 in production and 900 in R&D[110]. - Legislative efforts at both federal and state levels continue to propose changes affecting drug pricing and reimbursement methodologies, potentially impacting the company's operations[88]. Employee Relations and Corporate Initiatives - The company is developing an integrated ESG program to comply with evolving regulations, including the EU's Corporate Sustainability Reporting Directive[94]. - The company has not experienced significant labor disruptions, maintaining good relations with employees and collective bargaining in some regions[111]. - The company anticipates ongoing macroeconomic challenges affecting inflation and supply chains, which its global supply team is actively managing[109]. - In 2025, the company achieved an annual Days Away Rate (DAR) of 5.5, meeting its goal of not exceeding 6, significantly lower than the industry standard DAR of 22[113]. - The company launched the Bausch + Lomb AI Academy in 2025, providing employees with access to world-class AI courses tailored for all experience levels[119]. - The company implemented a women's health program in the United States in 2025, providing comprehensive support for various health-related issues[121]. - The ONE by ONE Recycling Program has collected over 114 million used contact lenses and related items since its launch in November 2016[123]. - The company’s revenues are historically weighted toward the second half of the year, with first-quarter sales typically lower due to patient co-pays and deductibles resetting[124]. - The company has a robust global succession planning process to identify and develop talent for critical leadership positions[120]. - The company’s total rewards philosophy includes base pay, short-term and long-term incentives, aimed at attracting and retaining employees[121]. Financial Position and Risk Management - As of December 31, 2025, the company had $3,695 million in variable rate debt and $1,412 million in fixed rate debt, with a €675 million principal amount requiring repayment in Euros[599]. - A 100 basis-point change in interest rates would have an annualized pre-tax effect of approximately $37 million on the company's earnings and cash flows[599]. - A 1% change in foreign currency exchange rates would have impacted the company's shareholders' equity by approximately $23 million as of December 31, 2025[598].

Learn AI or risk losing that bonus — that is the blunt mandate of Bausch + Lomb (BLCO) CEO Brent Saunders. "We have a responsibility as employers, as leaders, to equip our colleagues with all the tools necessary to thrive in an AI environment," Saunders told Yahoo Finance's Opening Bid, noting that the company is curating specific Coursera tracks by job type. The CEO added that the AI training prerequisite is mandatory as the company aims to ensure "we invest in our colleagues to not only upskill them, ...

Adjusted EBITDA in the fourth quarter was $330 million , up 27% , with an adjusted EBITDA margin of 23.5% , which Eldessouky said was the highest level the company has achieved as a standalone company since its IPO. Full-year adjusted EBITDA was $891 million , and adjusted EBITDA margin for the full year was 17.5% .CFO Sam Eldessouky reported total company revenue of $1.405 billion in the fourth quarter, up 7% on a constant-currency basis. Full-year revenue was $5.101 billion , up 5% , and up 6% excluding t ...

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.43%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.18, delivering a surprise of +12.5%.Over the last four quarters, the company ha ...

Bausch + Lomb (NYSE:BLCO) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Company ParticipantsAndrew Stewart - President of Global Pharmaceuticals and International ConsumerBrent Saunders - Chairman and CEODavid Roman - Managing DirectorDouglas Miehm - Managing DirectorGeorge Gadkowski - VP of Investor Relations and Business InsightsJoanne Wuensch - Managing Director, Head of U.S. Healthcare ResearchPatrick Wood - Managing DirectorSam Eldessouky - CFOYehia Hashad - EVP and Chief Medical OfficerConferenc ...

Bausch + Lomb (NYSE:BLCO) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Company ParticipantsAndrew Stewart - President of Global Pharmaceuticals and International ConsumerBrent Saunders - Chairman and CEODavid Roman - Managing DirectorDouglas Miehm - Managing DirectorGeorge Gadkowski - VP of Investor Relations and Business InsightsJoanne Wuensch - Managing Director, Head of U.S. Healthcare ResearchPatrick Wood - Managing DirectorSam Eldessouky - CFOYehia Hashad - EVP and Chief Medical OfficerConferenc ...

Bausch + Lomb (NYSE:BLCO) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Speaker9Please note this event is being recorded. I would now like to turn the conference over to George Gadkowski, Vice President of Investor Relations and Business Insights. Please go ahead.Speaker4Thank you. Good morning, everyone, and welcome to our fourth quarter 2025 financial results conference call. Participating on today's call are Chairman and Chief Executive Officer, Mr. Brent Saunders, Chief Financial Officer, Mr. Sam ...

4Q25 & FY25 Financial Results February 18, 2026 Forward-Looking Statements; Non-GAAP Information This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L"), including the Company's 2026 full-year guidance, our 3-year strategic plan and ...

Exhibit 99.1 Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter VAUGHAN, Ontario, Feb. 18, 2026 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2025 financial results. "We didn't just grow in the fourth quarter – we grew smarter," said Brent Sau ...